Canada's life and health insurance sector intensified its engagement with federal policymakers in the lead-up to the 2026 budget, as the government considers next steps for national pharmacare.
An analysis by advocacy group the Council of Canadians showed insurance lobbyists held dozens of meetings with federal officials in the second half of 2025, including representatives from Health Canada, the Department of Finance, the Prime Minister’s Office, MPs and senators. The meetings focused largely on the scope, funding and structure of the emerging pharmacare framework.
According to a report from NB Media Co-op., the lobbying push follows the passage of the Pharmacare Act in October 2024, which established the legal foundation for a universal drug program. Ottawa has since begun rolling out the initiative in stages, starting with coverage for contraceptives and diabetes medications. While the federal government has signed pharmacare agreements with several provinces and one territory, broader expansion of the program — and associated funding commitments — remain unresolved.
Industry participants argue that employer-sponsored drug plans already cover a majority of working Canadians and that any national pharmacare model should avoid disrupting existing benefits. Insurers and industry associations have said publicly that they support expanding access to prescription drugs, but favour approaches that preserve a role for private coverage alongside public plans.
For insurers, the stakes are significant. Prescription drug coverage is a core component of group benefits, and changes to public coverage could reshape plan design, pricing and risk allocation across the private market. A more expansive public pharmacare program could reduce demand for private drug benefits, while a narrower model could maintain space for supplemental insurance products, the report said.
Advocates of universal pharmacare counter that reliance on employer-based coverage leaves many Canadians exposed, particularly those who are unemployed, self-employed or working in precarious jobs. They argue a national program would improve affordability, consistency and access, while reducing out-of-pocket costs for households.
The heightened lobbying activity highlights the tension between public policy goals and the existing private insurance system as Ottawa weighs how far and how fast to move on pharmacare. With no comprehensive funding plan yet announced, the coming federal budget is expected to be a key signal of how the government intends to balance expanded public coverage with the continued role of private insurers.
